| 5.47 -0.05 (-0.91%) | 01-14 09:37 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.68 | 1-year : | 7.8 |
| Resists | First : | 5.71 | Second : | 6.68 |
| Pivot price | 4.95  |
|||
| Supports | First : | 4.79 | Second : | 4.23 |
| MAs | MA(5) : | 5.48 |
MA(20) : | 4.8 |
| MA(100) : | 4.05 |
MA(250) : | 3.32 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 92.6 |
D(3) : | 93.9 |
| RSI | RSI(14): 66.4 |
|||
| 52-week | High : | 5.78 | Low : | 1.84 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACHV ] has closed below upper band by 18.7%. Bollinger Bands are 56.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.66 - 5.69 | 5.69 - 5.71 |
| Low: | 5.26 - 5.3 | 5.3 - 5.32 |
| Close: | 5.47 - 5.52 | 5.52 - 5.56 |
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Tue, 13 Jan 2026
Achieve Life Sciences appoints Mark Rubinstein as permanent CMO By Investing.com - Investing.com Nigeria
Mon, 12 Jan 2026
Achieve Life Sciences (ACHV) Appoints New Chief Medical Officer - GuruFocus
Mon, 12 Jan 2026
Achieve Life Sciences Confirms Mark Rubinstein as Chief Medical Officer - Quiver Quantitative
Mon, 12 Jan 2026
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer - Yahoo Finance
Mon, 12 Jan 2026
Nicotine addiction expert takes lead medical role at Achieve Life Sciences - Stock Titan
Thu, 01 Jan 2026
When Will Achieve Life Sciences, Inc. (NASDAQ:ACHV) Become Profitable? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 40.6 (%) |
| Shares Short | 6,060 (K) |
| Shares Short P.Month | 6,320 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -65.5 % |
| Return on Equity (ttm) | -161.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -4.09 |
| PEG Ratio | 0 |
| Price to Book value | 8.62 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|